China’s coronavirus vaccine could be ready for trials next monthChinese officials say that a coronavirus vaccine could be ready for clinical trials and emergency situations next month Share XChina’s coronavirus vaccine could be ready for trials next monthhttps://pharmaphorum.com/news/chinese-coronavirus-vaccine-could-be-ready-for-trials-next-month/
Stem cell transplant eradicates HIV in second patientA second man with HIV has been cured of the infection after receiving a transplant of stem cells Share XStem cell transplant eradicates HIV in second patienthttps://pharmaphorum.com/news/stem-cell-transplant-eradicates-hiv-in-second-patient/
ViiV’s two-drug HIV therapy Dovato gets Japanese approvalOne of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new Share XViiV’s two-drug HIV therapy Dovato gets Japanese approvalhttps://pharmaphorum.com/news/viivs-two-drug-hiv-therapy-dovato-gets-japanese-approval/
ViiV files first-in-class HIV drug in EuropeViiV Healthcare has filed its new HIV drug fostemsavir for approval in Europe, a few weeks after the Share XViiV files first-in-class HIV drug in Europehttps://pharmaphorum.com/news/viiv-files-first-in-class-hiv-drug-in-europe/
FDA knocks back ViiV, J&J’s long-acting HIV regimenPeople with HIV hoping to be freed from daily doses of tablets will have to wait a little Share XFDA knocks back ViiV, J&J’s long-acting HIV regimenhttps://pharmaphorum.com/news/fda-knocks-back-viiv-jjs-long-acting-hiv-regimen/
ViiV presses go on FDA filing for first-in-class HIV drug fostemsavirViiV Healthcare has fulfilled its pledge of submitting its new HIV drug fostemsavir for approval before year end, Share XViiV presses go on FDA filing for first-in-class HIV drug fostemsavirhttps://pharmaphorum.com/news/viiv-presses-go-on-fda-filing-for-first-in-class-hiv-drug-fostemsavir/
Gilead’s Descovy approved in HIV prophylaxisThe FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of Share XGilead’s Descovy approved in HIV prophylaxishttps://pharmaphorum.com/news/gileads-descovy-approved-in-hiv-prophylaxis/
ViiV’s injection still suppresses HIV when taken every two months – studyGSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus Share XViiV’s injection still suppresses HIV when taken every two months – studyhttps://pharmaphorum.com/news/viivs-injection-still-suppresses-hiv-when-taken-every-two-months-study/
Gilead will challenge US government patent on PrEP drug TruvadaGilead Sciences has said it plans to challenge patents held by the US government on the use of Share XGilead will challenge US government patent on PrEP drug Truvadahttps://pharmaphorum.com/news/gilead-will-challenge-us-government-patent-on-prep-drug-truvada/
